Argenica Therapeutics (ASX: AGN) – Webinar Presentation
Liz Dallimore - CEO & Managing Director - Argenica Therapeutics is developing novel neuroprotective therapeutics to reduce brain damage after stroke.
Read More
Argenica Therapeutics Limited
Argenica Therapeutics was incorporated on 20/11/2019 as a proprietary Australian company to undertake the development and commercialisation of a novel drug based on the pioneering work of Professor Bruno Meloni and Clinical Professor Neville Knuckey at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute).
Spotlight Videos
Argenica Therapeutics (ASX: AGN) – Webinar Presentation
All Argenica Therapeutics Limited Content
News
Developing therapeutics to reduce brain damage after stroke
Presenter - Liz Dallimore - CEO - Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia.
Read More
